Point of Care Detection of Prostate Specific Antigen

Principal Investigator

Name
Takako Takeda

Degrees
Ph.D.

Institution
Triton Systems, Inc.

Position Title
Sr. Data Scientist

Email
ttakeda@tritonsys.com

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-1685

Initial CDAS Request Approval
Sep 30, 2024

Title
Point of Care Detection of Prostate Specific Antigen

Summary
Triton will develop a low-cost, at-home, paper-based vertical flow assay PSA detection test kit with prostate
cancer biopsy risk calculation algorithm based on our previously developed technologies with a classifier for
prostate cancer risk integrating the personal risk factors using a finger stick to obtain a blood sample at the
price less than $20.00. Successful development of a low cost, simple-to-use, home-based test kit for PSA
screening for prostate cancer with a classification algorithm will enable patients to decide whether to seek
medical help or keep monitoring, will be reducing cancer mortality especially for high risked population.

Aims

Our Aim 1 is to develop a rapid, ease of use, paper-based vertical flow assay prototype that patients can
administer to detect PSA based on triton’s previously developed technology. Aim 2 is to develop a classifier
model for PSA screening with the readout from the proposed device and patient’s personalized risk factors
including race, age, geography, and family history with machine learning technique. Anticipated end results
of the proposed Phase I efforts include a functional prototype for a point-of-care PSA screening blood test
with optimized reagent formulation with a classification model.

Collaborators

Dr. Jonathan Shoag – University Hospitals Cleveland & Case Western Reserve University

Dr. Alex Bryant – the University of Michigan